About this approach
CAR T-cell therapy is a personalized cellular immunotherapy. A treatment center collects a patient’s T cells, a laboratory adds a chimeric antigen receptor that recognizes a target on cancer cells, the engineered cells are expanded, and the center returns them by infusion after lymphodepleting chemotherapy. Current approved products are used for specific leukemias, lymphomas and multiple myeloma. Treatment is coordinated through specialized hospital cellular-therapy programs because collection, manufacturing, infusion, early monitoring and long-term follow-up form one connected pathway.
Where it fits: Established cellular immunotherapy for selected leukemias, lymphomas and multiple myeloma
Where this treatment is used
Current U.S. approvals cover product-specific uses in B-cell acute lymphoblastic leukemia, several B-cell lymphomas and multiple myeloma. The target, diagnosis, age range, prior-treatment requirements and line of therapy differ by product and jurisdiction. NCI lists the established autologous products and describes solid-tumor CAR T-cell treatment as clinical research. A CAR T-cell center reviews pathology, treatment history, disease status, organ function, infection status and the practical ability to complete collection, infusion and monitoring before scheduling the pathway.
Procedure and practical considerations
The treatment pathway may include referral review, insurance or public-program authorization, testing, leukapheresis, manufacturing time, treatment to control the cancer while cells are prepared, lymphodepleting chemotherapy, CAR T-cell infusion and close monitoring. Cytokine release syndrome and neurologic toxicity can require urgent hospital treatment. Other monitored issues include infection, low blood counts, immune-system effects and secondary malignancies. The exact monitoring period, caregiver plan, driving restrictions and required distance from the center follow the product and center protocol.
From referral to follow-up
- Referral and records review by a hematology or cellular-therapy team.
- Testing to confirm the cancer type, current disease status, organ function and treatment eligibility.
- Leukapheresis to collect white blood cells, including T cells.
- Laboratory engineering and expansion of the CAR T cells; manufacturing time depends on the product and program.
- Lymphodepleting chemotherapy shortly before infusion.
- CAR T-cell infusion, early observation and a center-specific plan for urgent symptoms.
- Ongoing blood tests, immune monitoring, cancer-response assessment and long-term follow-up.
Blood cancers treated with CAR T-cell products
Approved uses are defined by the exact product label and local regulator. Across current programs, CAR T-cell therapy is used for selected B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma and related large B-cell lymphomas, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma and multiple myeloma. A center confirms whether a product and funded or insured pathway applies to the diagnosis and treatment history.
CD19 and BCMA are the main established targets
CD19-directed products are used in selected leukemias and lymphomas. BCMA-directed products are used in multiple myeloma. FDA’s current licensed-product list includes Abecma, Aucatzyl, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta; individual indications and age ranges are found in each current prescribing label.
Information a CAR T-cell center may request
- Pathology reports and the exact blood-cancer diagnosis.
- A timeline of previous treatments, responses and dates of relapse or progression.
- Recent imaging, bone-marrow findings and laboratory results.
- Current medicines, infections, heart, lung, kidney, liver and neurologic history.
- Insurance authorization or public-program enrollment information.
- A caregiver, travel and temporary lodging plan for the center’s required monitoring period.
Questions that help compare programs
- Which CAR T-cell products and diagnoses does the center currently accept?
- Does the center treat adults, children, or both?
- Where do collection, infusion, inpatient care and follow-up take place?
- What happens during manufacturing, and who manages bridging treatment?
- How long must the patient and caregiver remain near the center?
- Who is contacted during nights and weekends if symptoms begin?
- Which costs are handled by the product program, insurer or public health system?
Clinics reporting this approach
These clinic profiles connect to this approach through clinic-confirmed selections or Cancer Clinic Finder’s source review. Open a profile to compare locations, services, practical details, and ways to get started.
227 connected profiles
Browse all 227 connected profilesSources
Source information checked: 2026-10-04. The links below identify the public and clinic-provided materials used for this page.
- NCI: T-cell Transfer Therapy ↗Checked 2026-10-04
- FDA: Approved Cellular and Gene Therapy Products ↗Checked 2026-10-04
- FDA: CAR T-cell class safety and boxed-warning information ↗Checked 2026-10-04
- NHS England: commissioned CAR T-cell treatment centres ↗Checked 2026-10-04
- Yescarta: authorized U.S. treatment center locator ↗Checked 2026-10-04
- FACT: official accredited cellular-therapy organizations ↗Checked 2026-10-04
How Cancer Clinic Finder compiles information · Suggest a factual correction